Literature DB >> 20093821

Reverse epidemiology, obesity and mortality in chronic kidney disease: modelling mortality expectations using energetics.

John R Speakman1, Klaas R Westerterp.   

Abstract

BACKGROUND/AIMS: Obesity is a predisposing factor for chronic illnesses such as type 2 diabetes, heart disease and cancer. In chronic kidney disease (CKD), the effect of obesity on mortality is reversed. Obese patients appear protected. Two ideas have been advanced to explain this 'reverse epidemiology'. First, obesity may buffer patients from wasting. Second, fat may sequester uraemic toxins leading to a systematic error in the prescription of dialysis. Our aim was to use data on the scaling of daily energy expenditure, fat and lean tissue mass to predict the pattern of variation in mortality with obesity under the contrasting hypotheses.
METHODS: We used data on daily energy demands measured using the doubly labelled water technique and body composition collected on a cohort of 503 individuals to model the expected impacts of wasting and fat sequestration/underdialysis on mortality.
RESULTS: A model predicting mortality due to wasting replicated the mortality pattern of the obesity paradox. However, quantitatively the beneficial effect of being fat was predicted to be much larger than that observed in the actual CKD population. Similar results were found for the fat sequestration/underdialysis hypothesis, but in this case the discrepancy was smaller. DISCUSSION: These models tend to support the fat sequestration and underdialysis idea more than the wasting hypothesis. In part (or in whole) this may be because of inadequacies in the model construction which are currently based on rather crude assumptions. Refinement of the models may enable better tests between alternative ideas for the obesity paradox. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093821     DOI: 10.1159/000245642

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  6 in total

1.  The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients.

Authors:  S Arsov; L Trajceska; W van Oeveren; A J Smit; P Dzekova; B Stegmayr; A Sikole; G Rakhorst; R Graaff
Journal:  Eur J Clin Nutr       Date:  2015-01-14       Impact factor: 4.016

2.  Genetic induction of phosphate toxicity significantly reduces the survival of hypercholesterolemic obese mice.

Authors:  Mutsuko Ohnishi; Shigeko Kato; M Shawkat Razzaque
Journal:  Biochem Biophys Res Commun       Date:  2011-10-20       Impact factor: 3.575

3.  Consilience in sarcopenia of cirrhosis.

Authors:  Srinivasan Dasarathy
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-05-31       Impact factor: 12.910

4.  Low cholesterol is associated with mortality from cardiovascular diseases: a dynamic cohort study in Korean adults.

Authors:  Jong-Myon Bae; Yeong-Ja Yang; Zhong-Min Li; Yoon-Ok Ahn
Journal:  J Korean Med Sci       Date:  2011-12-19       Impact factor: 2.153

5.  Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterol.

Authors:  Kuo-Liong Chien; Hung-Ju Lin; Hsiu-Ching Hsu; Ming-Fong Chen
Journal:  Lipids Health Dis       Date:  2011-11-19       Impact factor: 3.876

6.  The relationship between obesity and diabetic nephropathy in China.

Authors:  Hui-Mei Chen; Wen-Wen Shen; Yong-Chun Ge; Yi-De Zhang; Hong-Lang Xie; Zhi-Hong Liu
Journal:  BMC Nephrol       Date:  2013-03-25       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.